Biotie Therapies Corp. operates as a drug development company. It focuses on the development of drugs for neurodegenerative and psychiatric disorders. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease that is in Phase III development; NRL-1 a proprietary intranasal formulation of diazepam for the treatment of epilepsy; Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which is in Phase II trial. The company’s products also comprise BTT-1023 a monoclonal antibody for treatment of inflammatory diseases focusing on conducting Phase 2 clinical trial; and SYN120 an oral, potent, dual antagonist of the 5-HT6 and 5HT2a receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose. The company has strategic collaboration with UCB Pharma S.A. Biotie Therapies Corp. is based in Turku, Finland.
biotie therapies oyj (BTH1V:Helsinki)
Phone: 358 2274 8900
Fax: 358 2274 8910www.biotie.com
|No competitor information is available for BTH1V.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.